Brazil's health regulator has approved five new injectable GLP-1 drugs for diabetes and obesity care, a sign of how quickly this market is expanding now that Ozempic's patent has expired there. The same week brought a sharp financial setback for Novo Nordisk and new research pointing to both risks and possible new uses for these medications. Together, the updates show how fast this treatment category is moving on several fronts at once, and why it may be worth paying attention if you or a family member uses one of these drugs.
Anvisa's approval of five new injectable GLP-1 drugs came after the expiration of Ozempic's patent in Brazil in March, which opened the door to a wave of expedited regulatory reviews. This kind of patent expiration tends to invite more manufacturers into a market, which can eventually widen access and lower prices for patients who rely on these treatments for diabetes or obesity. Readers outside Brazil should watch whether similar patent timelines in their own countries lead to comparable regulatory movement, since that pattern often signals more competition ahead.
Novo Nordisk lost $30 billion in market value after one of its experimental drugs failed in trial, and analysts were critical of the result. A setback like this can affect how much a company invests in future research, which matters to patients who depend on a steady pipeline of new treatment options. It is a reminder that drug development carries real financial risk for manufacturers, even when a company already has a well established product on the market.
The Department of Veterans Affairs has launched a clinical trial testing a GLP-1 receptor drug for veterans dealing with both diabetes and alcoholism. This trial reflects a broader interest in whether GLP-1 medications, originally developed for blood sugar control and weight loss, might also help with alcohol use disorder. For veterans enrolled in the study, the outcome could open a new treatment path, and the results may also inform how these drugs are studied in other populations with similar struggles.
A separate clinical trial found that oral semaglutide may help curb heavy drinking in adults with alcohol use disorder, with participants showing improvements compared to those on a placebo. This finding adds to the growing body of research exploring GLP-1 drugs beyond their original purpose. If you are considering a GLP-1 medication for reasons outside diabetes or obesity, it would be wise to talk with your doctor about what the current evidence does and does not support, since this research is still developing.
A new study has linked GLP-1 use to a higher risk of non-scarring alopecia, a type of hair loss that is not permanent, compared to people who do not use these drugs. This finding does not mean hair loss will happen to every user, but it does add another item to the list of side effects patients may want to discuss with their prescriber. Anyone noticing unexpected hair thinning while on a GLP-1 medication should bring it up at their next appointment rather than assuming it is unrelated.
These five stories, taken together, show a treatment category that is expanding in availability while also facing new questions about safety and effectiveness beyond its original use. If you are currently taking a GLP-1 medication or considering one, I would suggest keeping an open conversation with your doctor about both the benefits you are seeking and any side effects you notice along the way. The research on alcohol use disorder and hair loss is still early, so it is reasonable to stay informed without changing your treatment plan based on a single study. As always, the right next step depends on your own health history and goals, and that conversation is best had directly with your care provider.
Key details
Anvisa in Brazil approved five new injectable GLP-1 drugs for diabetes and obesity care.
Novo Nordisk lost $30 billion in market value after a new drug trial failed.
The VA launched a clinical trial testing a GLP-1 drug for veterans with alcoholism.
A clinical trial found oral semaglutide may help curb heavy drinking in adults.
A new study links GLP-1 use to a higher risk of non-scarring hair loss.
Sources
Novo Nordisk’s Market Value Sheds $30 Billion-Here’s Why Shares Are Down — Forbes
VA announces launch of GLP-1 treatment to help veterans struggling with alcohol — Baltimore News
VA announces launch of GLP-1 treatment to help veterans struggling with alcohol — WJLA
Ozempic is giving people ‘temporal hollowing.’ What is it? — USA TODAY
Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions — Benzinga
Indiana Medicaid to opt into discounted obesity drug program — South Bend Tribune
Eli Lilly taps Ohio manufacturer to boost GLP-1 production — Cincinnati Cincinnati Enquirer
1 drugs like Ozempic increase hair loss risk? — Medical News Today